NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
NovaBridge Biosciences - American Depositary Shares (NBP)
Company Research
Source: GlobeNewswire
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge subsidiary company Visara, Inc., will also join the Board’s Research and Development Committee, established to expedite innovation and long-term growth ROCKVILLE, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines, today named Emmett T. Cunningham, Jr, MD, PhD, MPH, Co-Founder and Executive Chairman of Visara, Inc., as Vice Chairman of the NovaBridge Board of Directors (the Board). Dr. Cunningham wi
Show less
Read more
Impact Snapshot
Event Time:
NBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBP alerts
High impacting NovaBridge Biosciences - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
NBP
News
- NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric CancerGlobeNewswire
- I-Mab (NASDAQ:NBP) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d-)" rating on the stock.MarketBeat
- I-Mab (NASDAQ:NBP) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $9.00 price target on the stock.MarketBeat
- NovaBridge Announces Open Market Purchases by Executive Chairman, Fu WeiGlobeNewswire
- Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsightPR Newswire
NBP
Analyst Actions
- 2/6/26 - HC Wainwright
NBP
Sec Filings
- 2/19/26 - Form 6-K
- 2/17/26 - Form 6-K
- 2/6/26 - Form 6-K/A
- NBP's page on the SEC website